2024 RNDS | NMOSD and MOGAD Clinical Trials @wearesrna
2024 RNDS | NMOSD and MOGAD Clinical Trials  @wearesrna
Uploaded December 2024 | Updated November 2026, 3 hours ago
At the 2024 RNDS, Dr. Michael Levy of Massachusetts General Hospital discussed various therapeutic approaches for MOG antibody disease (MOGAD), transverse myelitis (TM), and neuromyelitis optica spectrum disorder (NMOSD), including acute therapy, preventive therapy, regenerative therapy, and symptomatic trials. Details were provided on specific trials such as the rozanolixizumab trial for MOGAD and the use of satralizumab for NMOSD [00:00:58]. Another focus was on a study investigating the impact of a dairy-free diet on MOG antibody levels [00:01:58]. Dr. Levy also mentioned acute treatment trials and the potential impact of cannabis-based products on improving quality of life for those diagnosed with NMOSD [00:11:16]. He concluded by answering audience questions [00:15:34]. Please note that the information shared during this session is for informational purposes only and is not medical advice.

You can view the presentation slides here:
files.wearesrna.org/symposia/2024_rnds/slides/2024RNDS_Levy.pdf

00:00 Introduction to MOGAD, TM, and NMOSD Trials
00:13 Understanding Acute and Preventive Therapies
00:32 Exploring Regenerative and Symptomatic Therapies
00:58 Current Trials in NMOSD
01:58 MOGAD Trials
02:28 Mechanism of Action: FcRn Blockers
04:19 Trial Design and Enrollment
05:38 Enspryng Trials for MOGAD
07:39 Dairy-Free Diet Study
11:16 Acute Treatment Trials
13:54 Nabiximols for NMOSD Quality of Life
15:28 Audience Questions
2024 RNDS | NMOSD and MOGAD Clinical Trials1214. Self Identity and Finding Meaning Following DiagnosisCommunity Meets Clinic 304. Dr. Ayşe Altıntaş2025 RNDS en Español | Bienvenida2024 Stronger Together | Journey Together: Reflecting and Shaping the Future2017 RNDS | Welcome and Goals2023 RNDS en Español | Una conversación con nuestros aliados de la industria sobre apoyo y recursos2025 RNDS en Español | Trastornos neuroinmunes poco frecuentes: mielitis transversa (MT)2026 RNDS | Research on Predicting MOGAD Patients at Risk for Relapse2025 RNDS | Upcoming therapies for MOGAD and NMOSD: Long-term therapeutics1311.  Understanding Myelitis: Efforts to Update Diagnostic Criteria2025 RNDS | Addressing Mental Health and Rare Neuroimmune Disorders
SRNA |

2024 RNDS | NMOSD and MOGAD Clinical Trials

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER